The Readout Loud 309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
Jun 6, 2024
STAT colleague Meghana Keshavan dissects Lykos Therapeutics' meeting with FDA. Topics include challenges in FDA approval for psychedelic therapy, Novartis's acquisition of Morphosis, ASCO conference reflections, and FDA advisory panel vote against MDMA for PTSD.
Chapters
Transcript
Episode notes
1 2 3 4 5
Intro
00:00 • 2min
Technical difficulties, dog's birthday, and travel adventures
01:33 • 2min
Insights from Bio and ASCO Conferences
03:30 • 6min
Novartis's Acquisition of Morphosis and FDA Approval Challenges
09:44 • 5min
MDMA for PTSD: FDA Advisory Panel Vote and Future Implications
14:18 • 15min